The CTTI Steering Committee (SC), made up of representatives from CTTI members across multiple sectors, provides input into decisions about CTTI priorities, projects and recommendations. Below, you will find a list of our SC members:
Eda Baykal-Caglar
Director of Clinical Research
Kathryn Capanna
Deputy Division Director, Office of Strategic Programs & Technology Innovation, DARSS
Marianne Chase
Senior Director of Clinical Trials Operations
Scott Evans, PhD, MS
Harvard University, Senior Research Scientist
Representing Society for Clinical Trials (SCT)
Jörg Goldhahn, MD
Medical Director at ETH and Director of Institute for Translational Medicine
Phil Green
Patient/Caregiver Representative
Karin Gulbrandsen
Sr. Director, US Cross Therapeutic Area Head
Sam Hariry
Global Head, Clinical Innovation, NIBR Translational Medicine
Christopher Houchens, PhD
Director Division of CBRN Countermeasures
Patricia Hurley, MSc
Director of Strategic Research Initiatives
Sameera Ibrahim
Head, R&D Quality Strategy & Business Operations at Bristol Myers Squibb
Julie Kaneshiro
Acting Director, Office for Human Research Protections
Office for Human Research Protections (Liaison)
Martin Landray, PhD, FRCP
Professor of Medicine & Epidemiology, Deputy Director - Big Data Institute
Michael Lincoff, MD
Director - C5 Research; Vice Chairman - Dept of Cardiovascular Medicine
Anna McDermott-Vitak
Senior Vice President & Managing Director Americas
Representing Drug Information Association (DIA)
Kristen Miller, PharmD
Health Science Policy Analyst, OMP
Nuru Noor
Patient/Caregiver Representative
Kelley O'Donoghue, MPH, CIP
Associate VP for Human Subject Protection, Executive Director IRB
Jamil Rivers
Patient/Caregiver Representative
James Rollins, MD
Acting Deputy Director of Division of Policy and Evidence Review
John Scott
Director, Division of Biostatics
Salinda Waddy
Associate Director and Chief, CTSA Program Clinical Affairs
Meghan Wagner
Health Scientist, Pharmacy Outcomes Research